Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.
- Prostate Cancer
- Eligible Ages
- Over 65 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Patients who have undergone CCP testing and patients who have not undergone CCP testing will be considered for enrollment in the study.
- Willing to provide written informed consent.
- Males ≥65 years old.
- Newly diagnosed (≤6 months), treatment-naïve patient with histologically proven localized adenocarcinoma of prostate whose initial treatment has not been decided.
- Candidate for and considering AS and yet would be eligible for definitive therapy.
- Favorable intermediate-risk disease, defined by the NCCN as follows:
- predominant Gleason grade 3; AND
- percentage of positive cores <50%; AND
- no more than 1 of the following NCCN intermediate-risk factors:
- Gleason grade 7
- PSA 10-20 ng/mL
- Estimated life expectancy ≥10 years.
- Can be monitored for disease progression according to standard of care (e.g., current NCCN guidelines).
- 1. Clinical evidence of metastasis or lymph node involvement.
- 2. Received pelvic radiation prior to biopsy.
- 3. Received androgen deprivation therapy (ADT) prior to biopsy; however, 5 alpha-reductase inhibitors (5-ARIs) are permitted.
- 4. Participation in interventional clinical trials.
- 5. Patient is considering watchful waiting.
- 6. Has a known history of hypogonadism.
- Study Type
- Observational [Patient Registry]
- Observational Model
- Time Perspective
|Prolaris Testing||Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing||
|No Prolaris Testing||Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing||
Homewood, Alabama 35209
Mesa, Arizona 85206
Little Rock, Arkansas 72211
Concord, California 94520
Jeremy Lieb, MD
Long Beach, California 90822
San Jose, California 95124
Daytona Beach, Florida 32114
Jonelle J Horsley
Delray Beach, Florida 33484
Saint Petersburg, Florida 33710
Sunrise, Florida 33351
Savannah, Georgia 31405
Coeur d'Alene, Idaho 83814
Westchester, Illinois 60154
Wichita, Kansas 67226
Shreveport, Louisiana 71106
Ann Arbor, Michigan 48109
Royal Oak, Michigan 48073
Troy, Michigan 48084
Tupelo, Mississippi 38801
Cranford, New Jersey 07016
Cranford, New Jersey 07016
Englewood, New Jersey 07631
Stony Brook, New York 11794
Syracuse, New York 13210
Raleigh, North Carolina 27612
Allentown, Pennsylvania 18103
West Columbia, South Carolina 29163
Nashville, Tennessee 37209
El Paso, Texas 79912
Burien, Washington 98166
- NCT ID
- Myriad Genetic Laboratories, Inc.
Study ContactBryan Dechairo, PhD
This is a long-term prospective registry to evaluate the impact of Prolaris testing on therapeutic decisions in patients with newly diagnosed favorable intermediate-risk localized prostate cancer and to summarize clinical oncologic outcomes. The design of the study is non-interventional, and therefore the protocol will not require a specific treatment plan for study participants. However, in the absence of a universally accepted timeframe for repeat biopsies within existing active surveillance recommendations, study sites will be encouraged to monitor patients for disease progression as per the standard of care (e.g., current National Comprehensive Cancer Network [NCCN] guidelines) with the expectation of a repeat biopsy within 18 months of the initial biopsy.
Patients who undergo Prolaris testing will be included in the registry as well as patients who do not undergo Prolaris testing. Data collection for the first primary objective extends over a 3-year period. During this time, data is collected on the treatment initiated, any follow-up prostate biopsy performed in patients initially treated with active surveillance, definitive treatments performed (with pathology data if surgical therapy is performed), and the reasons definitive treatment was pursued, as well as data related to disease progression such as biochemical recurrence, development of prostate cancer metastases, or disease specific death.
Data collection for the second primary objective extends out to 8 years. During this time data is collected on any follow-up prostate biopsy in patients still treated with active surveillance, definitive treatments performed (with pathology data if surgical therapy is performed), and the reasons definitive treatment was pursued, as well as data related to disease progression such as biochemical recurrence, development of prostate cancer metastases, or disease specific death.